
In this episode of Rheuminations, guest host Leonard H. Calabrese, DO, sits down with Peter Ulrichts, PhD, chief scientific officer at ArgenX, to discuss FcRn biology, from basic science to approved therapy.
· Introducing Peter Ulrichts, PhD. 1:10
· How did you go from this "basic biology" to first-in-man? 6:04
· What was the rationale behind the diseases that you chose for clinical trials? 13:58
· Is this where the story ends with efgartigimod (Vyvgart; Argenx)? 17:54
· Where do you see this going 10 years from now? 24:18
We'd love to hear from you! Send your comments/questions to Dr. Brown at [email protected]. Follow us on X @HRheuminations @AdamJBrownMD @HealioRheum. Follow Dr. Calabrese on X @LCalabreseDO
More episodes from "Healio Rheuminations"



Don't miss an episode of “Healio Rheuminations” and subscribe to it in the GetPodcast app.








